Literature DB >> 20687168

Overall and cause-specific survival for patients undergoing lobectomy, near-total, or total thyroidectomy for differentiated thyroid cancer.

Brandon M Barney1, Ying J Hitchcock, Pramod Sharma, Dennis C Shrieve, Jonathan D Tward.   

Abstract

BACKGROUND: The extent of surgery for well-differentiated thyroid cancer remains controversial. The purpose of this study was to evaluate the type of resection, age, T classification, nodal status, tumor size, and year of diagnosis for overall survival (OS) and cause-specific survival (CSS) using a large database.
METHODS: Using the Surveillance, Epidemiology, and End Results (SEER) database, 23,605 subjects were identified with papillary or follicular thyroid cancer between 1983 and 2002. OS and CSS were estimated, and outcomes for local excision, lobectomy, near-total thyroidectomy, or total thyroidectomy were compared.
RESULTS: Ten-year OS and CSS by surgery were: total thyroidectomy, 90.4% and 96.8%, respectively; near-total thyroidectomy, 89.5% and 96.6%, respectively; and lobectomy, 90.8% and 98.6%, respectively. Controlling for risk factors, near-total thyroidectomy was inferior to total thyroidectomy for OS (hazard ratio [HR] 1.21; p = .019) and CSS (HR 1.39; p = .019). Age, T3/T4 disease, positive nodes, and tumor size were associated with poorer outcomes.
CONCLUSION: Total thyroidectomy resulted in improved survival. Therapy should be individualized, accounting for potential complications and recurrence patterns.
Copyright © 2010 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2010        PMID: 20687168     DOI: 10.1002/hed.21504

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  44 in total

Review 1.  Current controversies and future directions in the diagnosis and management of differentiated thyroid cancers.

Authors:  Timothy M Ullmann; Katherine D Gray; Maureen D Moore; Rasa Zarnegar; Thomas J Fahey
Journal:  Gland Surg       Date:  2018-10

Review 2.  Controversies in the Management of Low-Risk Differentiated Thyroid Cancer.

Authors:  Megan R Haymart; Nazanene H Esfandiari; Michael T Stang; Julia Ann Sosa
Journal:  Endocr Rev       Date:  2017-08-01       Impact factor: 19.871

3.  Impact of Extent of Surgery on Tumor Recurrence and Survival for Papillary Thyroid Cancer Patients.

Authors:  Rajshri M Gartland; Carrie C Lubitz
Journal:  Ann Surg Oncol       Date:  2018-05-31       Impact factor: 5.344

Review 4.  Controversial Issues in Thyroid Cancer Management.

Authors:  R Michael Tuttle
Journal:  J Nucl Med       Date:  2018-04-13       Impact factor: 10.057

5.  The Positive Lymph Node Number and Postoperative N-Staging Used to Estimate Survival in Patients with Differentiated Thyroid Cancer: Results from the Surveillance, Epidemiology, and End Results Dataset (1988-2008).

Authors:  Wen-Jun Wei; Zhong-Wu Lu; Duo Wen; Tian Liao; Duan-Shu Li; Yu Wang; Yong-Xue Zhu; Zhuo-Ying Wang; Yi Wu; Yu-Long Wang; Qing-Hai Ji
Journal:  World J Surg       Date:  2018-06       Impact factor: 3.352

Review 6.  Differentiated thyroid cancer-personalized therapies to prevent overtreatment.

Authors:  Markus Luster; Theresia Weber; Frederik A Verburg
Journal:  Nat Rev Endocrinol       Date:  2014-07-01       Impact factor: 43.330

Review 7.  The role of surgery in the current management of differentiated thyroid cancer.

Authors:  Giovanni Conzo; Nicola Avenia; Giuseppe Bellastella; Giancarlo Candela; Annamaria de Bellis; Katherine Esposito; Daniela Pasquali; Andrea Polistena; Luigi Santini; Antonio Agostino Sinisi
Journal:  Endocrine       Date:  2014-04-10       Impact factor: 3.633

Review 8.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky
Journal:  Thyroid       Date:  2016-01       Impact factor: 6.568

Review 9.  Advances in surgical therapy for thyroid cancer.

Authors:  Haggi Mazeh; Herbert Chen
Journal:  Nat Rev Endocrinol       Date:  2011-08-23       Impact factor: 43.330

10.  Remnant uptake as a postoperative oncologic quality indicator.

Authors:  David F Schneider; Kristin A Ojomo; Herbert Chen; Rebecca S Sippel
Journal:  Thyroid       Date:  2013-07-17       Impact factor: 6.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.